Table 3.

Characteristics of patients with and without anti-SARS-CoV-2-S IgG seroconversion.

	Seroconversion N (%)	No seroconversion N (%)
Total	74 (100.0)	3 (100.0)
Median age, years (range)	55.6 (23.8-86.3)	56.9 (55.3-84.7)
Sex
Female	36 (48.6)	3 (100.0)
Male	38 (51.4)	0
Charlson comorbidity index
0	44 (59.5)	2 (66.7)
1-2	22 (29.7)	1 (33.3)
≥3	8 (10.8)	0
Severity of psoriasis
Moderate (Psoriasis Area and Severity Index <20)	63 (85.1)	3 (100.0)
Severe (Psoriasis Area and Severity Index ≥20)	11 (14.9)	0 (0.0)
Type of psoriasis treatment
Biologics	64 (86.5)	2 (66.7)
TNF-α inhibitor	14 (18.9)	2 (66.7)
Interleukin inhibitor	50 (67.6)	0
Interleukin 12-/13 inhibitor	8 (10.8)	0
Ustekinumab	8 (10.8)	0
Interleukin 17A inhibitor	21 (28.4)	0
Secukinumab	5 (6.8)	0
Ixekizumab	16 (21.6)	0
Interleukin 23 inhibitor	21 (28.4)	0
Tildrakizumab	9 (12.2)	0
Risankizumab	2 (2.7)	0
Guselkumab	10 (13.5)	0
Methotrexate 10-15 mg/week	8 (10.8)	1 (33.3)
Apremilast (Phosphodiesterase inhibitor)	1 (1.4)	0
Dimethyl fumarate	1 (1.4)	0
Immunosuppressive comedication for psoriasis
None	70 (94.6)	2 (66.7)
Prednisolon 5mg/daily	1 (1.4)	0
Methotrexate	3 (4.1)	1 (33.3)
Methotrexate 5 mg/week	1 (1.4)	1 (33.3)
Methorexate 7.5 mg/week	1 (1.4)	0
Methotrexate 10 mg/week	1 (1.4)	0
Methotrexate as main posriasis treatment or comedication
Yes	11 (14.9)	2 (66.7)
No	63 (85.1)	1 (33.3)
Leukocytes (3.6-9.2/nL)
Median (range)	7.3 (3.8-12.0)	7.0 (5.8-8.1)
Decreased		0
Within the normal range		3 (100.0)
Increased		0
Not available	6 (8.1)	0
Neutrophils (1.7-6.2/nL)
Median (range)	4.4(2.2-8.5)	4.5 (2.4-6.3)
Decreased	0	0
Within the normal range	59 (79.7)	2 (66.7)
Increased	8 (10.8)	1 (33.3)
Not available	7 (9.5)	0
Lymphocytes (1.0-3.4/nL)
Median (range)	1.8 (0.6-3.8)	1.6 (0.9-2.8)
Decreased	3 (4.1)	1 (33.3)
Within the normal range	58 (78.4)	2 (66.7)
Increased	6 (8.1)	0
Not available	7 (9.5)	0